Cost-Effectiveness of Zoledronic Acid Versus Oral Alendronate for Postmenopausal Osteoporotic Women in China

Overview

Journal Front Pharmacol

Date 2020 May 20

PMID 32425768

Citations 10

Authors

Ruxu You

Yu Zhang

David Bin-Chia Wu

Jinyu Liu

Xinyu Qian

Nan Luo

Takahiro Mori

Affiliations

Soon will be listed here.

Abstract

Objective: This study aims to estimate the cost-effectiveness of yearly intravenous zoledronic acid treatment versus weekly oral alendronate for postmenopausal osteoporotic women in China.

Methods: We used a Markov microsimulation model to compare the cost-effectiveness of zoledronic acid with alendronate in Chinese postmenopausal osteoporotic women with no fracture history at various ages of therapy initiation from health care payer perspective.

Results: The incremental cost-effectiveness ratios (ICERs) for the zoledronic acid versus alendronate were $23,581/QALY at age 65 years, $17,367/QALY at age 70 years, $14,714/QALY at age 75 years, and $12,169/QALY at age 80 years, respectively. In deterministic sensitivity analyses, the study demonstrated that the two most impactful parameters were the annual cost of zoledronic acid and the relative risk of hip fracture with zoledronic acid. In probabilistic sensitivity analyses, the probabilities of zoledronic acid being cost-effective compared with alendronate were 70-100% at a willingness-to-pay of $29,340 per QALY.

Conclusions: Among postmenopausal osteoporotic women in China, zoledronic acid therapy is cost-effective at all ages examined from health care payer perspective, compared with weekly oral alendronate. In addition, alendronate treatment is shown to be dominant for patients at ages 65 and 70 with full persistence. This study will help clinicians and policymakers make better decisions about the relative economic value of osteoporosis treatments in China.

Citing Articles

Zoledronic acid improves periodontal health, reduces serum inflammation, and enhances bone metabolism in postmenopausal osteoporosis complicated by periodontitis.

Xu G, Guo Y, Wang W, Yu W, Chen Q, Wang H Am J Transl Res. 2024; 16(11):6519-6527.

PMID: 39678564 PMC: 11645633. DOI: 10.62347/GXEB5902.

Alterations in macrophage polarization in the craniofacial and extracranial skeleton after zoledronate application and surgical interventions - an experiment.

Struckmeier A, Wehrhan F, Preidl R, Mike M, Monch T, Eilers L Front Immunol. 2023; 14:1204188.

PMID: 37292209 PMC: 10244663. DOI: 10.3389/fimmu.2023.1204188.

Prevalence of osteoporosis and incidence of related fractures in developed economies in the Asia Pacific region: a systematic review.

Chandran M, BrindAmour K, Fujiwara S, Ha Y, Tang H, Hwang J Osteoporos Int. 2023; 34(6):1037-1053.

PMID: 36735053 PMC: 10202996. DOI: 10.1007/s00198-022-06657-8.

Quantifying the Value of Introducing an Oral Drug Delivery Option for Edaravone: A Review of Analyses Evaluating the Economic Impact of Oral versus Intravenous Formulations.

Ronquest N, Paret K, Lucas A, Ciepielewska M, Hagan M Clinicoecon Outcomes Res. 2022; 14:499-511.

PMID: 35923520 PMC: 9342658. DOI: 10.2147/CEOR.S359025.

Cost-Effectiveness of Sequential Denosumab/Zoledronic Acid Compared With Zoledronic Acid Monotherapy for Postmenopausal Osteoporotic Women in China.

You R, Liu J, Ke L, Wan M, Zhang Y, Yu G Front Pharmacol. 2022; 13:816248.

PMID: 35370751 PMC: 8971554. DOI: 10.3389/fphar.2022.816248.

References

Murad M, Drake M, Mullan R, Mauck K, Stuart L, Lane M . Clinical review. Comparative effectiveness of drug treatments to prevent fragility fractures: a systematic review and network meta-analysis. J Clin Endocrinol Metab. 2012; 97(6):1871-80. DOI: 10.1210/jc.2011-3060. View

Si L, Winzenberg T, de Graaff B, Palmer A . A systematic review and meta-analysis of utility-based quality of life for osteoporosis-related conditions. Osteoporos Int. 2014; 25(8):1987-97. DOI: 10.1007/s00198-014-2636-2. View

Hiligsmann M, Ethgen O, Richy F, Reginster J . Utility values associated with osteoporotic fracture: a systematic review of the literature. Calcif Tissue Int. 2008; 82(4):288-92. DOI: 10.1007/s00223-008-9117-6. View

Mori T, Crandall C, Ganz D . Cost-effectiveness of combined oral bisphosphonate therapy and falls prevention exercise for fracture prevention in the USA. Osteoporos Int. 2016; 28(2):585-595. DOI: 10.1007/s00198-016-3772-7. View

Ito K . Cost-effectiveness of single-dose zoledronic acid for nursing home residents with osteoporosis in the USA. BMJ Open. 2018; 8(9):e022585. PMC: 6129093. DOI: 10.1136/bmjopen-2018-022585. View

Sozen T, Ozisik L, Calik Basaran N . An overview and management of osteoporosis. Eur J Rheumatol. 2017; 4(1):46-56. PMC: 5335887. DOI: 10.5152/eurjrheum.2016.048. View

Qu B, Ma Y, Yan M, Wu H, Fan L, Liao D . The economic burden of fracture patients with osteoporosis in western China. Osteoporos Int. 2014; 25(7):1853-60. DOI: 10.1007/s00198-014-2699-0. View

Wang J, Wang Y, Liu W, Wang F, Yin Z . Hip fractures in Hefei, China: the Hefei osteoporosis project. J Bone Miner Metab. 2013; 32(2):206-14. DOI: 10.1007/s00774-013-0484-3. View

Hiligsmann M, Reginster J, Tosteson A, Bukata S, Saag K, Gold D . Recommendations for the conduct of economic evaluations in osteoporosis: outcomes of an experts' consensus meeting organized by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases.... Osteoporos Int. 2018; 30(1):45-57. PMC: 6331734. DOI: 10.1007/s00198-018-4744-x. View

10.

Hiligsmann M, Rabenda V, Bruyere O, Reginster J . The clinical and economic burden of non-adherence with oral bisphosphonates in osteoporotic patients. Health Policy. 2010; 96(2):170-7. DOI: 10.1016/j.healthpol.2010.01.014. View

11.

Lin X, Xiong D, Peng Y, Sheng Z, Wu X, Wu X . Epidemiology and management of osteoporosis in the People's Republic of China: current perspectives. Clin Interv Aging. 2015; 10:1017-33. PMC: 4485798. DOI: 10.2147/CIA.S54613. View

12.

Cosman F, de Beur S, LeBoff M, Lewiecki E, Tanner B, Randall S . Clinician's Guide to Prevention and Treatment of Osteoporosis. Osteoporos Int. 2014; 25(10):2359-81. PMC: 4176573. DOI: 10.1007/s00198-014-2794-2. View

13.

Tremblay E, Perreault S, Dorais M . Persistence with denosumab and zoledronic acid among older women: a population-based cohort study. Arch Osteoporos. 2016; 11(1):30. DOI: 10.1007/s11657-016-0282-3. View

14.

Kanis J, Oden A, Johnell O, De Laet C, Jonsson B, Oglesby A . The components of excess mortality after hip fracture. Bone. 2003; 32(5):468-73. DOI: 10.1016/s8756-3282(03)00061-9. View

15.

Lofthus C, Frihagen F, Meyer H, Nordsletten L, Melhuus K, Falch J . Epidemiology of distal forearm fractures in Oslo, Norway. Osteoporos Int. 2007; 19(6):781-6. DOI: 10.1007/s00198-007-0499-5. View

16.

Stevenson M, Selby P . Modelling the cost effectiveness of interventions for osteoporosis: issues to consider. Pharmacoeconomics. 2014; 32(8):735-43. DOI: 10.1007/s40273-014-0156-8. View

17.

Wells G, Cranney A, Peterson J, Boucher M, Shea B, Robinson V . Risedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst Rev. 2008; (1):CD004523. DOI: 10.1002/14651858.CD004523.pub3. View

18.

Parthan A, Kruse M, Agodoa I, Silverman S, Orwoll E . Denosumab: a cost-effective alternative for older men with osteoporosis from a Swedish payer perspective. Bone. 2013; 59:105-13. DOI: 10.1016/j.bone.2013.11.002. View

19.

Marshall D, Johnell O, Wedel H . Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ. 1996; 312(7041):1254-9. PMC: 2351094. DOI: 10.1136/bmj.312.7041.1254. View

20.

Moriwaki K, Mouri M, Hagino H . Cost-effectiveness analysis of once-yearly injection of zoledronic acid for the treatment of osteoporosis in Japan. Osteoporos Int. 2017; 28(6):1939-1950. PMC: 5486933. DOI: 10.1007/s00198-017-3973-8. View